Therapeutic Kinase Inhibitors

·
· Current Topics in Microbiology and Immunology 第 355 冊 · Springer Science & Business Media
5.0
1 則評論
電子書
234
評分和評論未經驗證  瞭解詳情

關於本電子書

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

評分和評論

5.0
1 則評論

為這本電子書評分

歡迎提供意見。

閱讀資訊

智慧型手機與平板電腦
只要安裝 Google Play 圖書應用程式 Android 版iPad/iPhone 版,不僅應用程式內容會自動與你的帳戶保持同步,還能讓你隨時隨地上網或離線閱讀。
筆記型電腦和電腦
你可以使用電腦的網路瀏覽器聆聽你在 Google Play 購買的有聲書。
電子書閱讀器與其他裝置
如要在 Kobo 電子閱讀器這類電子書裝置上閱覽書籍,必須將檔案下載並傳輸到該裝置上。請按照說明中心的詳細操作說明,將檔案傳輸到支援的電子閱讀器上。